SPY334.19+5.46 1.66%
DIA275.90+4.20 1.55%
IXIC11,117.53+203.96 1.87%

Morgan Stanley Maintains Equal-Weight on Akebia Therapeutics, Lowers Price Target to $3

Morgan Stanley maintains Akebia Therapeutics (NASDAQ:AKBA) with a Equal-Weight and lowers the price target from $12 to $3.

· 09/04/2020 08:34
Morgan Stanley maintains Akebia Therapeutics (NASDAQ:AKBA) with a Equal-Weight and lowers the price target from $12 to $3.